<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Transl Allergy</journal-id><journal-id journal-id-type="iso-abbrev">Clin Transl Allergy</journal-id><journal-title-group><journal-title>Clinical and Translational Allergy</journal-title></journal-title-group><issn pub-type="epub">2045-7022</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7299638</article-id><article-id pub-id-type="publisher-id">333</article-id><article-id pub-id-type="doi">10.1186/s13601-020-00333-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Allergy clinics in times of the SARS-CoV-2 pandemic: an integrated model</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Malipiero</surname><given-names>Giacomo</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0492-5663</contrib-id><name><surname>Heffler</surname><given-names>Enrico</given-names></name><address><email>enrico.heffler@hunimed.eu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Pelaia</surname><given-names>Corrado</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Puggioni</surname><given-names>Francesca</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Racca</surname><given-names>Francesca</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ferri</surname><given-names>Sebastian</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Spinello</surname><given-names>Lina</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Merigo</surname><given-names>Morena</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lamacchia</surname><given-names>Donatella</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cataldo</surname><given-names>Giuseppe</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sansonna</surname><given-names>Melissa</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Canonica</surname><given-names>Giorgio Walter</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Paoletti</surname><given-names>Giovanni</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.417728.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 1756 8807</institution-id><institution>Personalized Medicine, Asthma and Allergy, </institution><institution>Humanitas Clinical and Research Center IRCCS, </institution></institution-wrap>Via Alessandro Manzoni 56, Rozzano, MI Italy </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.452490.e</institution-id><institution>Department of Biomedical Sciences, </institution><institution>Humanitas University, </institution></institution-wrap>Pieve Emanuele, MI Italy </aff><aff id="Aff3"><label>3</label>Department of Medical and Surgical Sciences, University &#x0201c;Magna Grecia&#x0201d; of Catanzaro, Catanzaro, Italy </aff></contrib-group><pub-date pub-type="epub"><day>18</day><month>6</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>18</day><month>6</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>10</volume><elocation-id>23</elocation-id><history><date date-type="received"><day>29</day><month>4</month><year>2020</year></date><date date-type="accepted"><day>11</day><month>6</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2020</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Almost the entire World is experiencing the Coronavirus-Disease-2019 (COVID-19) pandemic, responsible, at the end of May 2020, of more than five million people infected worldwide and about 350,000 deaths. In this context, a deep reorganization of allergy clinics, in order to ensure proper diagnosis and care despite of social distancing measures expose, is needed.</p></sec><sec><title>Main text</title><p id="Par2">The reorganization of allergy clinics should include programmed checks for severe and poorly controlled patients, application of digital medicine service for mild-to-moderate disease in well-controlled ones, postponement of non urgent diagnostic work-ups and domiciliation of therapies, whenever possible. As far as therapies, allergen immunotherapy (AIT) should not be stopped and sublingual immunotherapy (SLIT) fits perfectly for this purpose, since a drug home-delivery service can be activated for the entire pandemic duration. Moreover, biologic agents for severe asthma, chronic spontaneous urticaria and atopic dermatitis should be particularly encouraged to achieve best control possible of severe disease in times of COVID-19 and, whenever possible, home-delivery and self-administration should be the preferred choice.</p></sec><sec><title>Conclusion</title><p id="Par3">During COVID-19 pandemic, allergists have the responsibility of balancing individual patients&#x02019; needs with public health issues, and innovative tools, such as telemedicine and digital medicine services, can be helpful to reduce the risk of viral spreading while delivering up-to-date personalized care.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Allergy</kwd><kwd>Asthma</kwd><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>Pandemic</kwd><kwd>Immunotherapy</kwd><kwd>Biologicals</kwd><kwd>Telemedicine</kwd><kwd>Digital medicine service</kwd><kwd>Home delivery</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par23">The recent Coronavirus-Disease-2019 (COVID-19) pandemic has radically changed health priorities and the management of non Covid-19 diseases. At the time of writing (end of May 2020), more than five million people in the world have been infected and about three hundred and fifty thousand have died from COVID 19 [<xref ref-type="bibr" rid="CR1">1</xref>]. This has resulted in a deep reorganization of health-care systems in order to ensure diagnosis and care for patients and contemporaneously trying to expose them to the minimum risk of contracting the infection in hospital or outpatient clinics. In addition, there is continuous new scientific knowledge about the novel virus that changes the indications on how to treat and prevent it. In this perspective, allergists have to adapt to the change by managing their patients keeping in mind that some allergic diseases of the upper and lower airways, such as allergic rhinitis, chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma have symptoms in common with COVID-19.</p></sec><sec id="Sec2"><title>Clinical features of COVID-19 and differential diagnosis with allergic diseases</title><p id="Par24">The susceptibility to and severity of Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-Cov-2) infection positively correlate with age and comorbidities like hypertension, diabetes and cardiovascular disease [<xref ref-type="bibr" rid="CR2">2</xref>]. The spectrum of clinical presentations is variable, from asymptomatic and mild clinical symptoms to acute respiratory-distress syndrome (ARDS) [<xref ref-type="bibr" rid="CR3">3</xref>]. Adults with mild COVID-19 most commonly manifest fever, cough, conjunctivitis, fatigue and anosmia, which in some patients can be accompanied by runny nose and headache. In the more severe clinical presentations, the patient feels worsening dyspnoea and general exhaustion. Additional symptoms such as diarrhea are less common. When the virus affects the lung, it can cause interstitial pneumonia [<xref ref-type="bibr" rid="CR2">2</xref>]. The most severe manifestations appear to be related to an excessive immune system response (&#x0201c;cytokine storm&#x0201d;) that leads to development of ARDS and respiratory failure requiring invasive ventilation.</p><p id="Par25">Some allergic diseases, like allergic rhinitis, CRSwNP and asthma, can simulate symptoms of COVID-19: cough and dyspnoea are shared with asthma, while runny nose and headache are frequent symptoms in allergic rhinitis and CRSwNP. In addition, this pandemic started in the spring season when the majority of patients with seasonal allergies suffers from partially similar symptoms. Anxiety is associated to both chronic airways diseases and COVID-19 pandemic, acting as a confounding factor that should be carefully factored in when interpreting subjective symptoms. From a different perspective, it has been reported that COVID-19 patients might present with skin signs and symptoms of urticaria and eczema resembling those acute urticaria or drug reactions, thus posing a diagnostic challenge to dermatologists and allergists [<xref ref-type="bibr" rid="CR4">4</xref>]. Therefore, in this kind of patients, it is important to focus attention on symptoms typical for COVID-19, manly fever but also excessive fatigue and impaired sense of smell or taste, to obtain a correct diagnosis (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Two apps have been developed to assess both COVID-19 (MASK-COVID) and asthma/rhinitis (MASK-air, available in 18 languages). A combined MASK-air-COVID app will be launched and will differentiate rhinitis/asthma symptoms from those of COVID-19 (personal communication form Prof. Bousquet).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Differential diagnosis of allergic airway diseases and SARS-CoV-2 infection</p></caption><graphic xlink:href="13601_2020_333_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec3"><title>The need for mitigation efforts</title><p id="Par26">Healthcare systems have been implemented to ensure citizens&#x02019; right of receiving appropriate and prompt care, as declared by the bill of right of many European Countries. In pandemics, unanticipated stresses challenge healthcare systems efficiency and performance, given the acute extraordinary shifts in patients&#x02019; needs and allocation of resources. Of course, a number of measures can be enacted to slow the pace of epidemic spread and keep health-care systems accessible to everyone. That would translate into a more favorable distribution of resources, meantime allowing for serological tests, results of randomized double-blind placebo-controlled trials and mass vaccination to become available.</p><p id="Par27">The first and obvious measure is quarantining of infected individuals, which is nonetheless limited by the challenge of identifying and isolating asymptomatic individuals and the high false negative rate of microbiological screening tests [<xref ref-type="bibr" rid="CR5">5</xref>]. Next, use of protective equipment, especially by health-care providers, is a mainstay of mitigation strategy but might be limited by shortage of material or misuse due to lack of operative skills. In the context of uncontrollable spreading of communicable diseases, social limitations and home confinement are extreme measures, even though made more bearable by the availability of social digital technologies. To make social distancing more feasible, a number of issues should be addressed and, in the context of care delivering, reducing unnecessary direct patients&#x02019; interaction with health-care providers is a priority requiring maximum efforts to adapt to and may be prolonged to the post-pandemic period, according to transmission dynamics of SARS-CoV-2 [<xref ref-type="bibr" rid="CR6">6</xref>]. There is particular concern for aging individuals, where coexisting comorbidities and consequent polypharmacy carry the risk of adverse events in terms of loss of control of chronic diseases, lack of therapeutic adherence, drug-related adverse events and need for urgent care, which would put both the patient and health care providers at risk of infection. In addition, uncontrolled chronic airway diseases could contribute to SARS-CoV-2 dissemination through coughing or sneezing, especially during periods of increased pollen exposure. Delivering targeted educational programs and action plans to enact in case of disease exacerbation is essential. Patients should be routinely checked about their technical skills (e.g. inhaler use) and treatment adherence and remotely monitored for initial signs of physical or psychological decompensation, possibly by using mobile health technology [<xref ref-type="bibr" rid="CR7">7</xref>].</p></sec><sec id="Sec4"><title>Allergy clinic at COVID-19 times: the dawn of a new era for telemedicine and digital medicine</title><p id="Par28">Since allergic diseases are highly heterogeneous in severity and risk of exacerbation, both at inter- and intra-patient levels, in the event of acute outpatients&#x02019; service rationing aimed at mitigating virus spread, patients&#x02019; access to allergy services has to be rationalized [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. A gradual escalation in acute service reduction would be preferable but might not be applicable in case of tumultuous spread of the virus. Similarly, &#x0201c;phase 2&#x0201d; re-opening policies should be based on gradualism and prudence. To this aim, a risk-stratified approach can be applied by considering patients&#x02019; clinical needs and in accordance to local and institutional policies. Therefore, acute service reduction can be arranged through combinations of measures that could change form nation to nation according to local epidemiology and socio-political trends. In such a highly dynamic setting, it is difficult to forecast how long the pandemic will last and whether subsequent &#x0201c;waves&#x0201d; of COVID-19 will require additional lockdowns before herd immunity is reached or a vaccine becomes available. Thus integrated planning is essential to keep allergy clinics and allergists operative in the long-term.</p><p id="Par29">In general, acute access to allergic emergency or life-threatening acute events is mandatory even during pandemics. As to outpatients, scheduled in-person visits for severe and poorly controlled allergic diseases should be regularly provided, by instructing patients to enter the clinic in a precise time-range and respect social distancing. To reduce the risk of in-hospital spread of the infection, COVID-19 and COVID-19 free-zones can be created by predisposing check-points at COVID-19 free-zone entrance to detect patients with fever (&#x0003e;&#x02009;37.5&#x000a0;&#x000b0;C), screen for symptoms of active infection and/or contact with COVID-19 positive individuals. Conversely, accesses for mild-to-moderate disease in well-controlled patients can be transitioned to a digital medicine service (DMS), including phone, video and email consults [<xref ref-type="bibr" rid="CR10">10</xref>]. Telehealth has the advantage of respecting social distancing, thus reducing the risk of viral transmission. When patients experience worsening symptoms requiring timely evaluation, digital tele-triaging should be arranged in order to segregate patients suitable for remote monitoring and therapeutic adjustment (for example, by providing them with an up-to-date action plan) from those requiring in-person visits and access to health-care facilities. Psychological and physical barriers to treatment adherence and comorbidities causing loss of control might be safely addressed and resolved by teleconsultations. Moreover, digital teletriaging of patients experiencing worsening respiratory symptoms can provide an invaluable aid at suspecting COVID-19 and activating general practitioners to monitor and/or investigate suspected patients [<xref ref-type="bibr" rid="CR11">11</xref>]. Patients waiting for diagnostic work-up or experiencing troublesome lack of comfort with therapeutic recommendations can access to digital platforms in order to contact their caring specialist. Objective questionnaires administered on-line may help deal with patients who poorly perceive their symptoms. We specify that some of these clinical interventions and ascertainments may be provided by health providers collaborating with allergists in multidisciplinary teams, such as specialized nurses, dietitians, ENT physicians and psychologists.</p><p id="Par30">It should be noted that virtual care has to be delivered according to national laws and by licensed providers. This could represent a problem where laws governing virtual care are not available or not up-to-date to ever modernizing tools. Standardized digital platforms should be provided to patients and health-care providers, accessible through a digital identity, in order to avoid misconducts and retain information in case of legal allegations [<xref ref-type="bibr" rid="CR12">12</xref>]. Meantime, other more common and widespread tools might be used, provided a properly informed consent to being treated via telemedicine has been obtained from the patient, when admitted by national laws on general data protection.</p><p id="Par31">Diagnostic work-up can be postponed in the great majority of allergic diseases, provided affected patients are well instructed about avoidance of potential environmental triggers and treatment of acute events, also based on written action plans [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Anyway, diagnostic procedures should be reconsidered as soon as pandemic becomes more controlled and confinement de-escalation begins.</p><p id="Par32">Therapeutic management deserves particular attention. Whenever possible, therapeutic maneuvers not requiring hospital access should be domiciled.</p><p id="Par33">In SARS-Cov-2 negative, low-risk individuals, allergen immunotherapy (AIT) should not be stopped and actually can be started in naive patients provided the required infrastructure is in place during the pandemic [<xref ref-type="bibr" rid="CR15">15</xref>]. We underline that sublingual immunotherapy (SLIT) for airborne allergens allows not suspending AIT and can be a valid and safe alternative for patients about to undergo SCIT, as far as a drug home-delivering service is activated by the local Pharmacy [<xref ref-type="bibr" rid="CR9">9</xref>]. This can prove a fruitful advantage of SLIT over subcutaneous immunotherapy (SCIT), in keeping patients adherent to AIT; transition from SCIT to SLIT might be considered as a possible management strategy during COVID-19 pandemic. SCIT for hymenoptera venom allergy should be continued although increasing administration interval can be considered during long-term maintenance. In confirmed or suspected COVID-19 patients, AIT should not be started and should be temporarily interrupted if already prescribed. AIT-specific recommendations are summarized in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> [<xref ref-type="bibr" rid="CR15">15</xref>].<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>AIT recommendations</p><p>(adapted from Klimek et al. 2020), [<xref ref-type="bibr" rid="CR19">19</xref>]</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Recommendations in non COVID-19 individuals</th></tr></thead><tbody><tr><td align="left">Interrupting subcutaneous immunotherapy is not advised. Especially in potentially life-threatening allergies, such as venom allergy, SCIT should be regularly continued. The possibility of expanding injection intervals in the continuation phase should be checked and may be beneficial</td></tr><tr><td align="left">Interrupting sublingual immunotherapy is not advised. Supply the patient with sufficient medication for a minimum of 14&#x000a0;days isolation</td></tr><tr><td align="left">Sublingual immunotherapy can be taken at home. The intake of SLIT by the patient at home or any place is advantageous in avoiding contact with potentially infected persons</td></tr><tr><td align="left">Both subcutaneous and sublingual immunotherapy can be continued in the current COVID-19 pandemics, in any asymptomatic patient without suspicion for SARS-CoV-2 infection and/or contact with SARS-CoV-2 positive individuals, in any patient with negative test result (RT-PCR) or in any patient after an adequate quarantine or with detection of serum IgG to SARS-CoV-2 without virus-specific IgM</td></tr><tr><td align="left">Preparedness of your Allergy clinic is imperative to cope with COVID-19. Follow World Health Organization (WHO) guidelines and advice staff accordingly</td></tr><tr><td align="left">These recommendations are conditional since there is paucity of data and they should be revised regularly with incoming new information on COVID-19</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left">Recommendations in COVID-19 diagnosed cases or suspicion for SARS-CoV-2 infection</th></tr></thead><tbody><tr><td align="left">Interrupting subcutaneous immunotherapy is advised</td></tr><tr><td align="left">Interrupting sublingual immunotherapy is advised</td></tr><tr><td align="left">Both subcutaneous and sublingual immunotherapy should be discontinued in symptomatic patients with exposure or contact with SARS-CoV-2 positive individuals, or patients with positive test results (RT-PCR)</td></tr></tbody></table></table-wrap></p><p id="Par34">First line anti-allergy agents, such as anti-histamines and low-dose steroids, are not likely to affect immunocompetence and should not be discontinued during the pandemic (for disease specific recommendations, see&#x000a0;&#x0201c;<xref rid="Sec5" ref-type="sec">Disease-specific management</xref>&#x0201d; section), provided systemic corticosteroid posology remains under the immunosuppressive threshold [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>] and that all strategies to reduce systemic corticosteroid use should be applied independently from the pandemic [<xref ref-type="bibr" rid="CR19">19</xref>]. Notably, regular steroid-based regimens, including inhaled and oral corticosteroids, should not be stopped, since abrupt interruption would bring along an increased risk of adrenal insufficiency in case of acute stressing events, as COVID-19 is [<xref ref-type="bibr" rid="CR20">20</xref>]. Conversely, a pulsed dose of steroids could result in a protective effect in such a circumstance [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par35">Second-line steroid sparing immunomodulating agents are potentially detrimental on immunity although clear-cut distinctions exist between nonspecific immunosuppressive drugs, like cyclosporine and azathioprine, and biological agents targeting discrete molecular pathways associated with type 2 allergic inflammation. In fact, besides inducing nonspecific suppression of anti-infective immunity, nonbiological agents are strong inducers of hepatic cytochromes, thus requiring plasma level monitoring when used in combination with antimicrobial agents [<xref ref-type="bibr" rid="CR22">22</xref>]. According to a WAO paper [<xref ref-type="bibr" rid="CR23">23</xref>], no definitive evidence is presently available to obligate clinical decision making. As anti-IgE, ant-IL5/IL5R and anti IL4/IL3R biologics are not likely to induce immunosuppression or interfere with virus clearance (actually the contrary seems to hold true, at least for omalizumab [<xref ref-type="bibr" rid="CR24">24</xref>] and dupilumab [<xref ref-type="bibr" rid="CR25">25</xref>], while mepolizumab treatment was not associated with worse immunological response to viruses [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]), they can be safely continued. Anyway, until evidence-based data are available, some countries, like the UK, have advised home confinement for at least 12&#x000a0;weeks to patients with severe asthma on systemic immunosuppressants or biological therapy. Steroid-sparing effect of biologics is a potential advantage over steroid therapy since patients on chronic steroid therapy can be affected by subclinical adrenal insufficiency [<xref ref-type="bibr" rid="CR20">20</xref>]. Depending on the specific monoclonal antibody, in-site administration or home-delivery and self-administration can be the preferred choice. When patients live far away from the Centre, National Networks can be activated in order to identify a local near-home Centre for in-site administration (in Italy the Severe Asthma Network in Italy (SANI) [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]). In case of infection, discontinuation should be discussed on a case-by-case basis.</p><p id="Par36">We should also consider the complexity of allergic patients and the synchronous atopic involvement of multiple organs that interface with the environment&#x02019;. Therefore, as far as precision medicines targeting nodal pathogenic pathways allow to treat &#x0201c;atopy&#x0201d; as a whole, we claim priority and lower prescription threshold could be assigned to biologicals, given the good safety profile, the lack of interference with drug metabolism and the favorable effect on treatment adherence. The regulatory agencies should address these new needs in pandemic times and coordinate with health care purchasers to make biological more accessible.</p><p id="Par37">Clinical research has been seriously threatened by COVID-19 epidemics. New recruitments in ongoing clinical trials have been temporarily suspended. Investigators can consult with sponsors in order to reassess follow-up visit schedules and amend protocol requirements to facilitate online visits. When accorded with the Sponsor and local Pharmacy, investigational product home-delivery service and a digital medicine service can be activated to administer scheduled questionnaires and monitor domiciliary drug self-administration [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par38">Disease-specific measures and therapeutic recommendations are rapidly provided in the following sections and graphically resumed in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>. In the case of atopic multimorbidity, priority should be given to uncontrolled/severe components over well-controlled/mild ones.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>An integrated model of tele- and digital-allergy clinic during COVID-19 pandemic. Suggested actions to be implemented in order to re-organize an allergy clinic are reported in boxes for asthma, rhino-conjunctivitis, atopic dermatitis and food allergy, anaphylaxis, drug and venom hypersensitivity and CSU. The truck represents the home-delivery service that should be activated for biologicals, AIT and self-injectable adrenaline</p></caption><graphic xlink:href="13601_2020_333_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec5"><title>Disease-specific management</title><sec id="Sec6"><title>Asthma</title><p id="Par39">Asthma-specific recommendations from Global Initiative for Asthma (GINA) are reported in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> [<xref ref-type="bibr" rid="CR30">30</xref>]. Data are controversial regarding the interaction between asthma and COVID-19 as European and Chinese data suggest a lower risk for asthmatic patients to contract the infection [<xref ref-type="bibr" rid="CR31">31</xref>] while U.S. data suggest the opposite [<xref ref-type="bibr" rid="CR32">32</xref>]. Probably this association is modulated by the severity of asthma, age class, and levels of indoor and outdoor, allergen and pollution exposures. With knowledge evolving, GINA and the British National Institute for Health and Care Excellence (NICE) guidelines recommend not stopping the regular treatment regimen, including inhaled and oral corticosteroids [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR33">33</xref>], since abrupt interruption would bring along an increased risk of acute/severe exacerbations or adrenal insufficiency [<xref ref-type="bibr" rid="CR21">21</xref>]. Every patient should be provided with a detailed and convenient action plan to deal with potential loss of control [<xref ref-type="bibr" rid="CR13">13</xref>], and invited to regularly use mobile health technology apps to self-monitor symptoms of their asthma [<xref ref-type="bibr" rid="CR7">7</xref>]. Aerosol generating procedures are discouraged unless essential and lung function testing should be postponed whenever possible [<xref ref-type="bibr" rid="CR30">30</xref>].<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Asthma-specific recommendations from Global Initiative for Asthma (GINA) as reported on GINA website [<xref ref-type="bibr" rid="CR34">34</xref>]</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left">People with asthma should continue all of their inhaled medication, including inhaled corticosteroids, as prescribed by their doctor</td></tr><tr><td align="left">In acute asthma attacks patients should take a short course of oral corticosteroids if instructed in their asthma action plan or by their healthcare provider, to prevent serious consequences</td></tr><tr><td align="left">In rare cases, patients with severe asthma might require long-term treatment with oral corticosteroids (OCS) on top of their inhaled medication(s). This treatment should be continued at the lowest possible dose in these patients at risk of severe attacks/exacerbations. Biologic therapies should be used in severe asthma patients who qualify for them, in order to limit the need for OCS as much as possible</td></tr><tr><td align="left"><p>Nebulizers should, where possible, be avoided for acute attacks due to the increased risk of disseminating COVID-19 (to other patients AND to physicians, nurses and other personnel)</p><p>&#x000a0;Pressurized metered dose inhaler (pMDI) via a spacer is the preferred treatment during severe attacks. (Spacers must not be shared at home)</p><p>&#x000a0;While a patient is being treated for a severe attack, their maintenance inhaled asthma treatment should be continued (at home AND in the hospital)</p></td></tr><tr><td align="left">Patients with allergic rhinitis should continue to take their nasal corticosteroids, as prescribed by their clinician</td></tr><tr><td align="left">Routine spirometry testing should be suspended to reduce the risk of viral transmission, and if absolutely necessary, adequate infection control measures should be taken</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec7"><title>Allergic rhino-conjunctivitis</title><p id="Par40">Allergic rhino-conjunctivitis-specific recommendations from allergic rhinitis and its impact on asthma (ARIA) and European Academy of Allergy and Clinical Immunology (EAACI) are reported in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Allergic rhinitis visits should not be prioritized and can be safely postponed unless exceptional circumstances supervene. Intranasal steroids do not induce immunosuppression and are not to discontinue [<xref ref-type="bibr" rid="CR34">34</xref>]. As stated above, optimal disease control is mandatory as sneezing in asymptomatically infected patients can contribute to viral spread; mobile applications can contribute in improving optimal self-management of rhinitis [<xref ref-type="bibr" rid="CR7">7</xref>]. For AIT-specific recommendations, see Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> [<xref ref-type="bibr" rid="CR15">15</xref>].<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Allergic rhino-conjunctivitis-specific recommendations from ARIA/EAACI (from: Bousquet et al. 2020) [<xref ref-type="bibr" rid="CR37">37</xref>]</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left">With the current knowledge, in patients with COVID-19 infection, intra-nasal corticosteroid (including spray) can be continued in allergic rhinitis at the recommended dose</td></tr><tr><td align="left">Stopping local intra-nasal corticosteroid is not advised. Suppression of the immune system has not been proven and more sneezing after stopping means more spreading of the Coronavirus</td></tr><tr><td align="left">These recommendations are conditional since there is a paucity of data and they should be revised regularly with new knowledge</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec8"><title>Chronic rhinosinusitis</title><p id="Par41">We are unaware of specific recommendations from medical societies about this topic. For reasons analogous to those specified for allergic rhino-conjunctivitis, it is commonsense to keep patients on regular treatments. Patients with uncontrolled disease or waiting for Ear-Nose-Throat (ENT) surgery could be transitioned to biological treatment whenever possible.</p></sec><sec id="Sec9"><title>Atopic dermatitis and food allergy</title><p id="Par42">Disseminated skin viral infections are a major complication of severe/uncontrolled atopic dermatitis. It is unknown whether increased risk of SARS-Cov-2 infection or disease severity is associated with atopic dermatitis due to impaired cutaneous barrier. Patients on immunosuppressive therapy for severe atopic dermatitis should be strictly monitored or transitioned to safer anti-IL4/IL13 immune-modulatory agents, as advocated by the European Task Force on atopic dermatitis [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. Safe use of Dupilumab in severe AD patients affected by COVID-19 has been recently reported [<xref ref-type="bibr" rid="CR37">37</xref>]. Food allergy and allergic gastrointestinal diseases are prevalent comorbidities in atopic dermatitis, especially in children; careful evaluation is needed and food challenge should be performed to prevent unnecessary food avoidance interfering with growth and micronutrients balance [<xref ref-type="bibr" rid="CR38">38</xref>]. Food allergy in asthma is of particular concern since it has been associated with fatal asthma. Asthmatic patients with food allergies may need to be provided with epinephrine auto injectors (see the following section on anaphylaxis management) and should avoid introducing new foods in their diets during the pandemic as long as the risk of contagion is high [<xref ref-type="bibr" rid="CR38">38</xref>].</p></sec><sec id="Sec10"><title>Anaphylaxis</title><p id="Par43">A modified anaphylaxis management algorithm during COVID-19 pandemic has been proposed by Casale et al. [<xref ref-type="bibr" rid="CR39">39</xref>]. Patients are invited to carry two epinephrine injectors and to activate emergency services only when a second administration of epinephrine fails to control symptoms. It might be prudent to proactively discuss the modified management of anaphylaxis, if feasible, e.g., via telemedicine. Home delivery service of self-injectable adrenaline should be implemented, provided the patient has been instructed on the underlying disease, triggers avoidance measures and proper use.</p></sec><sec id="Sec11"><title>Drug allergy, hymenoptera venom allergy and urticaria/angioedema</title><p id="Par44">Expert recommendations and consensus on these topics during COVID-19 epidemics are missing at the time of this manuscript being written. As a general principle, we maintain that ongoing treatment for these conditions should not to be discontinued in order to keep disease under control as far as these treatments are not likely to increase the risk of SARS-Cov-2 infection or complicate COVID-19 course in case of infection. A possible exception might be represented by patients on immunosuppressive regimens (e.g. cyclosporine for chronic spontaneous urticaria), in whom shift to a biological agent with a more favorable safety profile might be considered on a case-by-case basis (e.g. close contact with infected individuals, active infection) [<xref ref-type="bibr" rid="CR40">40</xref>]. For new evaluations, diagnostic procedures should be postponed during the epidemics peak and reconsidered on a second time, unless urgently needed (e.g. severe reactions to Hymenoptera venom). We highlight that urticaria can be a presenting sign of COVID-19 and allergy to drugs used to treat COVID-19 can present with rashes that may involve the allergist&#x02019;s evaluation [<xref ref-type="bibr" rid="CR4">4</xref>].</p></sec></sec><sec id="Sec12"><title>Conclusion</title><p id="Par45">We are now in the middle of the storm and we do not know how long it will last or whether additional consequences are on the horizon. In these times of suspense, we have the responsibility of balancing individual patients&#x02019; needs with public health issues. To our mind, a black-and-white thinking does not suit a scientific way of addressing theoretical and practical problems. We therefore advocate for a risk-stratified approach aimed at conjugating COVID-19 and non-COVID-19 health care needs of allergic patients. We have to reshape our practice and optimize those innovative tools that help us reduce the risk of viral spreading while delivering up-to-date personalized care. A new era of integrated precision-digital medicine is knocking at the door.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ACE-2</term><def><p id="Par4">Angiotensin-converting enzyme-2</p></def></def-item><def-item><term>AIT</term><def><p id="Par5">Allergen immunotherapy</p></def></def-item><def-item><term>ARDS</term><def><p id="Par6">Acute respiratory distress syndrome</p></def></def-item><def-item><term>ARIA</term><def><p id="Par7">Allergic rhinitis and its impact on asthma</p></def></def-item><def-item><term>COVID-19</term><def><p id="Par8">Coronavirus-Disease 2019</p></def></def-item><def-item><term>CRSwNP</term><def><p id="Par9">Chronic rhinosinusitis with nasal polyps</p></def></def-item><def-item><term>DMS</term><def><p id="Par10">Digital medicine service</p></def></def-item><def-item><term>EAACI</term><def><p id="Par11">European Academy of Allergy and Clinical Immunology</p></def></def-item><def-item><term>ENT</term><def><p id="Par12">Ear-Nose-Throat</p></def></def-item><def-item><term>GINA</term><def><p id="Par13">Global initiative for asthma</p></def></def-item><def-item><term>NICE</term><def><p id="Par14">National Institute for Health and Care Excellence</p></def></def-item><def-item><term>OCS</term><def><p id="Par15">Oral corticosteroids</p></def></def-item><def-item><term>pMDI</term><def><p id="Par16">Pressurized metered dose inhaler</p></def></def-item><def-item><term>SANI</term><def><p id="Par17">Severe Asthma Network in Italy</p></def></def-item><def-item><term>SARS-CoV-2</term><def><p id="Par18">Severe Acute Respiratory Syndrome-Coronavirus-2</p></def></def-item><def-item><term>SCIT</term><def><p id="Par19">Subcutaneous immunotherapy</p></def></def-item><def-item><term>SLIT</term><def><p id="Par20">Sublingual immunotherapy</p></def></def-item><def-item><term>TLR</term><def><p id="Par21">Toll-like receptor</p></def></def-item><def-item><term>WHO</term><def><p id="Par22">World Health Organization</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Author&#x02019;s contributions</title><p>GM, GP, EH and GWC contributed in conception and drafting the review article; CP, FP, FR, SF, LS, DL, GC, MM, MS: contributed in critically interpret and revise the article. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>No funds for this review article.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>Not applicable.</p></notes><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par46">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par47">Requested (pending) (for reproducing Tables&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab3" ref-type="table">3</xref>).</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par48">Enrico Heffler reports personal fees from AstraZeneca, Sanofi, Novartis, Teva, GSK, Circassia, Boehringer Ingelheim, Valeas, Nestl&#x000e8; Purina, outside the submitted work. Giorgio Walter Canonica reports grants and personal fees from Menarini, Alk Abello&#x02019;, Anallergo Boehringer Ingelheim, Chiesi, Circassia, Genentech, Guidotti Malesci, GSK, Hal Allergy, Meda, Merck, Merck Sharp &#x00026; Dome Novartis Recordati-InnuvaPharma, Roche, Sanofi Stallergenes, UCB Pharma, Uriach Pharma, Teva Astrazeneca, Thermo Fisher, Valeas, Vibor Pharma, outside the submitted work. Francesca Puggioni reports personal fees from Astrazeneca, Chiesi, GSK, Guidotti, Menarini, Mundipharma Novartis, Sanofi, Valeas, Allergy Therapeutics, Almirall outside the submitted work. Giovanni Paoletti reports personal fees from Novartis and Lusofarma, outside the submitted work. Giacomo Malipiero reports personal fees from Allergy Therapeutics, outside the submitted work. Francesca Racca, Corrado Pelaia, Sebastian Ferri, Donatella Lamacchia, Giuseppe Cataldo, Lina Spinello, Melissa Sansonna, and Morena Merigo do not have potential conflict of interest to declare.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">World Health Organization (WHO) Cornavirus-19 (COVID-19), <ext-link ext-link-type="uri" xlink:href="https://covid19.who.int">https://covid19.who.int</ext-link>. Accessed 28 May 2020.</mixed-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>F</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name></person-group><article-title>Facing a major outbreak of new coronavirus infections in 2019: thoughts of pediatricians [J]</article-title><source>Chin J Pediatr.</source><year>2020</year><volume>58</volume><issue>2</issue><fpage>81</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.3760/cma.j.issn.0578-1310.2020.02.001</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmadpoor</surname><given-names>P</given-names></name><name><surname>Rostaing</surname><given-names>L</given-names></name></person-group><article-title>Why the immune system fails to mount an adaptive immune response to a Covid -19 infection</article-title><source>Transpl Int</source><year>2020</year><pub-id pub-id-type="doi">10.1111/tri.13611</pub-id><?supplied-pmid 32236983?><pub-id pub-id-type="pmid">32236983</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Recalcati</surname><given-names>S</given-names></name></person-group><article-title>Cutaneous manifestations in COVID-19: a first perspective</article-title><source>J Eur Acad Dermatol Venereol</source><year>2020</year><volume>34</volume><issue>5</issue><fpage>e212</fpage><lpage>e213</lpage><pub-id pub-id-type="doi">10.1111/jdv.16387</pub-id><?supplied-pmid 32215952?><pub-id pub-id-type="pmid">32215952</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Zhong</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Zheng</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name></person-group><article-title>Chest CT for Typical 2019-nCoV Pneumonia: relationship to Negative RT-PCR Testing</article-title><source>Radiology</source><year>2020</year><pub-id pub-id-type="doi">10.1148/radiol.2020200343</pub-id><?supplied-pmid 32484415?><pub-id pub-id-type="pmid">32484415</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kissler</surname><given-names>SM</given-names></name><name><surname>Tedijanto</surname><given-names>C</given-names></name><name><surname>Goldstein</surname><given-names>E</given-names></name><name><surname>Grad</surname><given-names>YH</given-names></name><name><surname>Lipsitch</surname><given-names>M</given-names></name></person-group><article-title>Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period</article-title><source>Science</source><year>2020</year><volume>368</volume><issue>6493</issue><fpage>860</fpage><lpage>868</lpage><pub-id pub-id-type="doi">10.1126/science.abb5793</pub-id><?supplied-pmid 32291278?><pub-id pub-id-type="pmid">32291278</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bousquet</surname><given-names>J</given-names></name><name><surname>Arnavielhe</surname><given-names>S</given-names></name><name><surname>Bedbrook</surname><given-names>A</given-names></name><etal/></person-group><article-title>MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence</article-title><source>Clin Transl Allergy.</source><year>2018</year><volume>8</volume><fpage>45</fpage><pub-id pub-id-type="doi">10.1186/s13601-018-0227-6</pub-id><?supplied-pmid 30386555?><pub-id pub-id-type="pmid">30386555</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaker</surname><given-names>MS</given-names></name><name><surname>Oppenheimer</surname><given-names>J</given-names></name><name><surname>Grayson</surname><given-names>M</given-names></name><name><surname>Stukus</surname><given-names>D</given-names></name><name><surname>Hartog</surname><given-names>N</given-names></name><name><surname>Hsieh</surname><given-names>EWY</given-names></name><name><surname>Rider</surname><given-names>N</given-names></name><name><surname>Dutmer</surname><given-names>CM</given-names></name><name><surname>Vander Leek</surname><given-names>TK</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Chan</surname><given-names>ES</given-names></name><name><surname>Mack</surname><given-names>D</given-names></name><name><surname>Ellis</surname><given-names>AK</given-names></name><name><surname>Lang</surname><given-names>D</given-names></name><name><surname>Lieberman</surname><given-names>J</given-names></name><name><surname>Fleischer</surname><given-names>D</given-names></name><name><surname>Golden</surname><given-names>DBK</given-names></name><name><surname>Wallace</surname><given-names>D</given-names></name><name><surname>Portnoy</surname><given-names>J</given-names></name><name><surname>Mosnaim</surname><given-names>G</given-names></name><name><surname>Greenhawt</surname><given-names>M</given-names></name></person-group><article-title>COVID-19: pandemic contingency planning for the allergy and immunology clinic</article-title><source>J Allergy Clin Immunol Pract.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.jaip.2020.03.012</pub-id><?supplied-pmid 32499040?><pub-id pub-id-type="pmid">32499040</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malipiero</surname><given-names>G</given-names></name><name><surname>Paoletti</surname><given-names>G</given-names></name><name><surname>Puggioni</surname><given-names>F</given-names></name><name><surname>Racca</surname><given-names>F</given-names></name><name><surname>Ferri</surname><given-names>S</given-names></name><name><surname>Marsala</surname><given-names>A</given-names></name><name><surname>Leoncini</surname><given-names>O</given-names></name><name><surname>Porli</surname><given-names>M</given-names></name><name><surname>Pieri</surname><given-names>G</given-names></name><name><surname>Canonica</surname><given-names>GW</given-names></name><name><surname>Heffler</surname><given-names>E</given-names></name></person-group><article-title>An academic allergy unit during COVID-19 pandemic in Italy</article-title><source>J Allergy Clin Immunol.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.jaci.2020.04.003</pub-id><?supplied-pmid 32317114?><pub-id pub-id-type="pmid">32317114</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krishna</surname><given-names>MT</given-names></name><name><surname>Knibb</surname><given-names>RC</given-names></name><name><surname>Huissoon</surname><given-names>AP</given-names></name></person-group><article-title>Is there a role for telemedicine in adult allergy services?</article-title><source>Clin Exp Allergy</source><year>2016</year><volume>46</volume><issue>5</issue><fpage>668</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.1111/cea.12701</pub-id><?supplied-pmid 26742680?><pub-id pub-id-type="pmid">26742680</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davarpanah</surname><given-names>AH</given-names></name><name><surname>Mahdavi</surname><given-names>A</given-names></name><name><surname>Sabri</surname><given-names>A</given-names></name><name><surname>Langroudi</surname><given-names>TF</given-names></name><name><surname>Kahkouee</surname><given-names>S</given-names></name><name><surname>Haseli</surname><given-names>S</given-names></name><name><surname>Kazemi</surname><given-names>MA</given-names></name><name><surname>Mehrian</surname><given-names>P</given-names></name><name><surname>Mahdavi</surname><given-names>A</given-names></name><name><surname>Falahati</surname><given-names>F</given-names></name><name><surname>Tuchayi</surname><given-names>AM</given-names></name><name><surname>Bakhshayeshkaram</surname><given-names>M</given-names></name><name><surname>Taheri</surname><given-names>MS</given-names></name></person-group><article-title>Novel screening and triage strategy in Iran during deadly Coronavirus Disease 2019 (COVID-19) Epidemic: value of Humanitarian Teleconsultation Service</article-title><source>J Am Coll Radiol.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.jacr.2020.03.015</pub-id><?supplied-pmid 32208138?><pub-id pub-id-type="pmid">32208138</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portnoy</surname><given-names>J</given-names></name><name><surname>Waller</surname><given-names>M</given-names></name><name><surname>Elliott</surname><given-names>T</given-names></name></person-group><article-title>Telemedicine in the Era of COVID-19</article-title><source>J Allergy Clin Immunol Pract.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.jaip.2020.03.008</pub-id><?supplied-pmid 32499037?><pub-id pub-id-type="pmid">32499037</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rank</surname><given-names>MA</given-names></name><name><surname>Volcheck</surname><given-names>GW</given-names></name><name><surname>Li</surname><given-names>JT</given-names></name><name><surname>Patel</surname><given-names>AM</given-names></name><name><surname>Lim</surname><given-names>KG</given-names></name></person-group><article-title>Formulating an effective and efficient written asthma action plan</article-title><source>Mayo Clin Proc</source><year>2008</year><volume>83</volume><issue>11</issue><fpage>1263</fpage><lpage>1270</lpage><pub-id pub-id-type="doi">10.4065/83.11.1263</pub-id><?supplied-pmid 18990325?><pub-id pub-id-type="pmid">18990325</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Sicherer</surname><given-names>SH</given-names></name></person-group><article-title>Section on allergy and immunology. Guidance on completing a written allergy and anaphylaxis emergency plan</article-title><source>Pediatrics</source><year>2017</year><volume>139</volume><issue>3</issue><fpage>e20164005</fpage><pub-id pub-id-type="doi">10.1542/peds.2016-4005</pub-id><?supplied-pmid 28193793?><pub-id pub-id-type="pmid">28193793</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klimek</surname><given-names>L</given-names></name><name><surname>Jutel</surname><given-names>M</given-names></name><name><surname>Akdis</surname><given-names>C</given-names></name><name><surname>Bousquet</surname><given-names>J</given-names></name><name><surname>Akdis</surname><given-names>M</given-names></name><name><surname>Bachert</surname><given-names>C</given-names></name><name><surname>Agache</surname><given-names>I</given-names></name><name><surname>Ansotegui</surname><given-names>I</given-names></name><name><surname>Bedbrook</surname><given-names>A</given-names></name><name><surname>Bosnic-Anticevich</surname><given-names>S</given-names></name><name><surname>Canonica</surname><given-names>GW</given-names></name><name><surname>Chivato</surname><given-names>T</given-names></name><name><surname>Cruz</surname><given-names>AA</given-names></name><name><surname>Czarlewski</surname><given-names>W</given-names></name><name><surname>Giacco</surname><given-names>SD</given-names></name><name><surname>Du</surname><given-names>H</given-names></name><name><surname>Fonseca</surname><given-names>JA</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Haahtela</surname><given-names>T</given-names></name><name><surname>Hoffmann-Sommergruber</surname><given-names>K</given-names></name><name><surname>Ivancevich</surname><given-names>JC</given-names></name><name><surname>Khaltaev</surname><given-names>N</given-names></name><name><surname>Knol</surname><given-names>EF</given-names></name><name><surname>Kuna</surname><given-names>P</given-names></name><name><surname>Larenas-Linnemann</surname><given-names>D</given-names></name><name><surname>Melen</surname><given-names>E</given-names></name><name><surname>Mullol</surname><given-names>J</given-names></name><name><surname>Naclerio</surname><given-names>R</given-names></name><name><surname>Ohta</surname><given-names>K</given-names></name><name><surname>Okamoto</surname><given-names>Y</given-names></name><name><surname>O&#x02019;Mahony</surname><given-names>L</given-names></name><name><surname>Onorato</surname><given-names>GL</given-names></name><name><surname>Papadopoulos</surname><given-names>NG</given-names></name><name><surname>Pawankar</surname><given-names>R</given-names></name><name><surname>Pfaar</surname><given-names>O</given-names></name><name><surname>Samolinski</surname><given-names>B</given-names></name><name><surname>Schwarze</surname><given-names>J</given-names></name><name><surname>Toppila-Salmi</surname><given-names>S</given-names></name><name><surname>Shamji</surname><given-names>MH</given-names></name><name><surname>Ventura</surname><given-names>MT</given-names></name><name><surname>Valiulis</surname><given-names>A</given-names></name><name><surname>Yorgancioglu</surname><given-names>A</given-names></name><name><surname>Matricardi</surname><given-names>P</given-names></name><name><surname>Zuberbier</surname><given-names>T</given-names></name><collab>ARIA-MASK study group</collab></person-group><article-title>Handling of allergen immunotherapy in the COVID-19 pandemic: an ARIA-EAACI statement</article-title><source>Allergy</source><year>2020</year><pub-id pub-id-type="doi">10.1111/all.14336</pub-id><?supplied-pmid 32535955?><pub-id pub-id-type="pmid">32535955</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arabi</surname><given-names>YM</given-names></name><name><surname>Mandourah</surname><given-names>Y</given-names></name><name><surname>Al-Hameed</surname><given-names>F</given-names></name><name><surname>Sindi</surname><given-names>AA</given-names></name><name><surname>Al Mekhlafi</surname><given-names>GA</given-names></name><name><surname>Hussein</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Corticosteroid therapy for critically Ill patients with the Middle East respiratory syndrome</article-title><source>Am J Respir Crit Care Med</source><year>2018</year><volume>197</volume><issue>6</issue><fpage>757</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1164/rccm.201706-1172OC</pub-id><pub-id pub-id-type="pmid">29161116</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>X</given-names></name><name><surname>Mei</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Tong</surname><given-names>F</given-names></name><name><surname>Geng</surname><given-names>S</given-names></name><name><surname>Pan</surname><given-names>A</given-names></name></person-group><article-title>Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19</article-title><source>J Infect</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.jinf.2020.03.039</pub-id><?supplied-pmid 32360498?><pub-id pub-id-type="pmid">32360498</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Ni Q, Ding C, Li YT, Zhao H, Liu J, Zhang X, et al. Retrospective study of low-to-moderate dose glucocorticoids on viral clearance in patients with novel coronavirus pneumonia. Chin J Clin Infect Dis. 2020,13 (2020-02-28). <ext-link ext-link-type="uri" xlink:href="http://rs.yiigle.com/yufabiao/1182773.htm">http://rs.yiigle.com/yufabiao/1182773.htm</ext-link>. Accessed 20 Mar 2020.</mixed-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heffler</surname><given-names>E</given-names></name><name><surname>Bagnasco</surname><given-names>D</given-names></name><name><surname>Canonica</surname><given-names>GW</given-names></name></person-group><article-title>Strategies to reduce corticosteroid-related adverse events in asthma</article-title><source>Curr Opin Allergy Clin Immunol</source><year>2019</year><volume>19</volume><issue>1</issue><fpage>61</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1097/aci.0000000000000493</pub-id><?supplied-pmid 30407207?><pub-id pub-id-type="pmid">30407207</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woods</surname><given-names>CP</given-names></name><name><surname>Argese</surname><given-names>N</given-names></name><name><surname>Chapman</surname><given-names>M</given-names></name><name><surname>Boot</surname><given-names>C</given-names></name><name><surname>Webster</surname><given-names>R</given-names></name><name><surname>Dabhi</surname><given-names>V</given-names></name><name><surname>Grossman</surname><given-names>AB</given-names></name><name><surname>Toogood</surname><given-names>AA</given-names></name><name><surname>Arlt</surname><given-names>W</given-names></name><name><surname>Stewart</surname><given-names>PM</given-names></name><name><surname>Crowley</surname><given-names>RK</given-names></name><name><surname>Tomlinson</surname><given-names>JW</given-names></name></person-group><article-title>Adrenal suppression in patients taking inhaled glucocorticoids is highly prevalent and management can be guided by morning cortisol</article-title><source>Eur J Endocrinol</source><year>2015</year><volume>173</volume><issue>5</issue><fpage>633</fpage><lpage>642</lpage><pub-id pub-id-type="doi">10.1530/EJE-15-0608</pub-id><pub-id pub-id-type="pmid">26294794</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaiser</surname><given-names>UB</given-names></name><name><surname>Mirmira</surname><given-names>RG</given-names></name><name><surname>Stewart</surname><given-names>PM</given-names></name></person-group><article-title>Our response to COVID-19 as endocrinologists and diabetologists</article-title><source>J Clin Endocrinol Metab</source><year>2020</year><volume>105</volume><issue>5</issue><fpage>dgaa148</fpage><pub-id pub-id-type="doi">10.1210/clinem/dgaa148</pub-id><?supplied-pmid 32232480?><pub-id pub-id-type="pmid">32232480</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ning</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yao</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>D</given-names></name><name><surname>Nashan</surname><given-names>B</given-names></name><name><surname>Shen</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>L</given-names></name></person-group><article-title>Novel Coronavirus (SARS-CoV-2) infection in a renal transplant recipient: case report</article-title><source>Am J Transplant</source><year>2020</year><pub-id pub-id-type="doi">10.1111/ajt.15897</pub-id><?supplied-pmid 32277555?><pub-id pub-id-type="pmid">32277555</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morais-Almeida</surname><given-names>M</given-names></name><name><surname>Aguiar</surname><given-names>R</given-names></name><name><surname>Martin</surname><given-names>B</given-names></name><name><surname>Ansotegui</surname><given-names>IJ</given-names></name><name><surname>Ebisawa</surname><given-names>M</given-names></name><name><surname>Arruda</surname><given-names>LK</given-names></name><name><surname>Caminati</surname><given-names>M</given-names></name><name><surname>Canonica</surname><given-names>GW</given-names></name><name><surname>Carr</surname><given-names>T</given-names></name><name><surname>Chupp</surname><given-names>G</given-names></name><name><surname>Corren</surname><given-names>J</given-names></name><name><surname>D&#x000e1;vila</surname><given-names>I</given-names></name><name><surname>Park</surname><given-names>HS</given-names></name><name><surname>Hanania</surname><given-names>NA</given-names></name><name><surname>Rosenwasser</surname><given-names>L</given-names></name><name><surname>S&#x000e1;nchez-Borges</surname><given-names>M</given-names></name><name><surname>Virchow</surname><given-names>JC</given-names></name><name><surname>Y&#x000e1;&#x000f1;ez</surname><given-names>A</given-names></name><name><surname>Bernstein</surname><given-names>JA</given-names></name><name><surname>Caraballo</surname><given-names>L</given-names></name><name><surname>Chang</surname><given-names>YS</given-names></name><name><surname>Chikhladze</surname><given-names>M</given-names></name><name><surname>Fiocchi</surname><given-names>A</given-names></name><name><surname>Gonz&#x000e1;lez-Diaz</surname><given-names>SN</given-names></name><name><surname>Tanno</surname><given-names>LK</given-names></name><name><surname>Levin</surname><given-names>M</given-names></name><name><surname>Ortega-Martell</surname><given-names>JA</given-names></name><name><surname>Passalacqua</surname><given-names>G</given-names></name><name><surname>Peden</surname><given-names>DB</given-names></name><name><surname>Rouadi</surname><given-names>PW</given-names></name><name><surname>Sublett</surname><given-names>JL</given-names></name><name><surname>Wong</surname><given-names>GWK</given-names></name><name><surname>Bleecker</surname><given-names>ER</given-names></name></person-group><article-title>COVID-19, asthma, and biologic therapies: what we need to know</article-title><source>World Allergy Organ J.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.waojou.2020.100126</pub-id><?supplied-pmid 32426090?><pub-id pub-id-type="pmid">32426090</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esquivel</surname><given-names>A</given-names></name><name><surname>Busse</surname><given-names>WW</given-names></name><name><surname>Calatroni</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effects of omalizumab on rhinovirus infections, illnesses, and exacerbations of asthma</article-title><source>Am J Respir Crit Care Med</source><year>2017</year><volume>196</volume><issue>8</issue><fpage>985</fpage><lpage>992</lpage><pub-id pub-id-type="doi">10.1164/rccm.201701-0120oc</pub-id><?supplied-pmid 28608756?><pub-id pub-id-type="pmid">28608756</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eichenfield</surname><given-names>LF</given-names></name><name><surname>Bieber</surname><given-names>T</given-names></name><name><surname>Beck</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis</article-title><source>Am J Clin Dermatol</source><year>2019</year><volume>20</volume><issue>3</issue><fpage>443</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1007/s40257-019-00445-7</pub-id><?supplied-pmid 31066001?><pub-id pub-id-type="pmid">31066001</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabogal Pi&#x000f1;eros</surname><given-names>YS</given-names></name><name><surname>Bal</surname><given-names>SM</given-names></name><name><surname>Pol</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Anti-IL-5 in mild asthma alters rhinovirus-induced macrophage, B-Cell, and neutrophil responses (MATERIAL). A placebo-controlled, double-blind study</article-title><source>Am J Respir Crit Care Med</source><year>2019</year><volume>199</volume><issue>4</issue><fpage>508</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1164/rccm.201803-0461oc</pub-id><?supplied-pmid 30192638?><pub-id pub-id-type="pmid">30192638</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabogal Pi&#x000f1;eros</surname><given-names>YS</given-names></name><name><surname>Bal</surname><given-names>SM</given-names></name><name><surname>Dijkhuis</surname><given-names>A</given-names></name><etal/></person-group><article-title>Eosinophils capture viruses, a capacity that is defective in asthma</article-title><source>Allergy</source><year>2019</year><volume>74</volume><issue>10</issue><fpage>1898</fpage><lpage>1909</lpage><pub-id pub-id-type="doi">10.1111/all.13802</pub-id><?supplied-pmid 30934128?><pub-id pub-id-type="pmid">30934128</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senna</surname><given-names>G</given-names></name><name><surname>Guerriero</surname><given-names>M</given-names></name><name><surname>Paggiaro</surname><given-names>PL</given-names></name><name><surname>Blasi</surname><given-names>F</given-names></name><name><surname>Caminati</surname><given-names>M</given-names></name><name><surname>Heffler</surname><given-names>E</given-names></name><name><surname>Latorre</surname><given-names>M</given-names></name><name><surname>Canonica</surname><given-names>GW</given-names></name></person-group><article-title>SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma</article-title><source>Clin Mol Allergy.</source><year>2017</year><volume>15</volume><fpage>9</fpage><pub-id pub-id-type="doi">10.1186/s12948-017-0065-4</pub-id><pub-id pub-id-type="pmid">28400707</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heffler</surname><given-names>E</given-names></name><name><surname>Blasi</surname><given-names>F</given-names></name><name><surname>Latorre</surname><given-names>M</given-names></name></person-group><article-title>The Severe Asthma Network in Italy: findings and Perspectives</article-title><source>J Allergy Clin Immunol Pract.</source><year>2019</year><volume>7</volume><issue>5</issue><fpage>1462</fpage><lpage>1468</lpage><pub-id pub-id-type="doi">10.1016/j.jaip.2018.10.016</pub-id><?supplied-pmid 30368004?><pub-id pub-id-type="pmid">30368004</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="other">Global initiative for asthma (GINA). Answers to frequently asked questions on asthma management, release date: March 25 2020. <ext-link ext-link-type="uri" xlink:href="https://www.ginasthma.org">https://www.ginasthma.org</ext-link>. Accessed 20 Apr 2020. </mixed-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>JJ</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>YY</given-names></name><name><surname>Yuan</surname><given-names>YD</given-names></name><name><surname>Yang</surname><given-names>YB</given-names></name><name><surname>Yan</surname><given-names>YQ</given-names></name><name><surname>Akdis</surname><given-names>CA</given-names></name><name><surname>Gao</surname><given-names>YD</given-names></name></person-group><article-title>Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China</article-title><source>Allergy.</source><year>2020</year><pub-id pub-id-type="doi">10.1111/all.14238</pub-id><?supplied-pmid 32544252?><pub-id pub-id-type="pmid">32544252</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garg</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>L</given-names></name><name><surname>Whitaker</surname><given-names>M</given-names></name><name><surname>O&#x02019;Halloran</surname><given-names>A</given-names></name><name><surname>Cummings</surname><given-names>C</given-names></name><name><surname>Holstein</surname><given-names>R</given-names></name><name><surname>Prill</surname><given-names>M</given-names></name><name><surname>Chai</surname><given-names>SJ</given-names></name><name><surname>Kirley</surname><given-names>PD</given-names></name><name><surname>Alden</surname><given-names>NB</given-names></name><name><surname>Kawasaki</surname><given-names>B</given-names></name><name><surname>Yousey-Hindes</surname><given-names>K</given-names></name><name><surname>Niccolai</surname><given-names>L</given-names></name><name><surname>Anderson</surname><given-names>EJ</given-names></name><name><surname>Openo</surname><given-names>KP</given-names></name><name><surname>Weigel</surname><given-names>A</given-names></name><name><surname>Monroe</surname><given-names>ML</given-names></name><name><surname>Ryan</surname><given-names>P</given-names></name><name><surname>Henderson</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Como-Sabetti</surname><given-names>K</given-names></name><name><surname>Lynfield</surname><given-names>R</given-names></name><name><surname>Sosin</surname><given-names>D</given-names></name><name><surname>Torres</surname><given-names>S</given-names></name><name><surname>Muse</surname><given-names>A</given-names></name><name><surname>Bennett</surname><given-names>NM</given-names></name><name><surname>Billing</surname><given-names>L</given-names></name><name><surname>Sutton</surname><given-names>M</given-names></name><name><surname>West</surname><given-names>N</given-names></name><name><surname>Schaffner</surname><given-names>W</given-names></name><name><surname>Talbot</surname><given-names>HK</given-names></name><name><surname>Aquino</surname><given-names>C</given-names></name><name><surname>George</surname><given-names>A</given-names></name><name><surname>Budd</surname><given-names>A</given-names></name><name><surname>Brammer</surname><given-names>L</given-names></name><name><surname>Langley</surname><given-names>G</given-names></name><name><surname>Hall</surname><given-names>AJ</given-names></name><name><surname>Fry</surname><given-names>A</given-names></name></person-group><article-title>Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed Coronavirus Disease 2019&#x02014;COVID-NET, 14 States, March 1&#x02013;30, 2020</article-title><source>MMWR Morb Mortal Wkly Rep</source><year>2020</year><volume>69</volume><issue>15</issue><fpage>458</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm6915e3</pub-id><?supplied-pmid 32298251?><pub-id pub-id-type="pmid">32298251</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">National Institute for Health and Care Excellence. COVID-19 rapid guideline: severe asthma. NG166, Published date: 03 April 2020. <ext-link ext-link-type="uri" xlink:href="http://www.nice.org.uk/guidance/ng166">www.nice.org.uk/guidance/ng166</ext-link>. Accessed 20 Apr 2020.</mixed-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bousquet</surname><given-names>J</given-names></name><name><surname>Akdis</surname><given-names>C</given-names></name><name><surname>Jutel</surname><given-names>M</given-names></name><name><surname>Bachert</surname><given-names>C</given-names></name><name><surname>Klimek</surname><given-names>L</given-names></name><name><surname>Agache</surname><given-names>I</given-names></name><name><surname>Ansotegui</surname><given-names>IJ</given-names></name><name><surname>Bedbrook</surname><given-names>A</given-names></name><name><surname>Bosnic-Anticevich</surname><given-names>S</given-names></name><name><surname>Canonica</surname><given-names>GW</given-names></name><name><surname>Chivato</surname><given-names>T</given-names></name><name><surname>Cruz</surname><given-names>AA</given-names></name><name><surname>Czarlewski</surname><given-names>W</given-names></name><name><surname>DelGiacco</surname><given-names>S</given-names></name><name><surname>Du</surname><given-names>H</given-names></name><name><surname>Fonseca</surname><given-names>JA</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Haahtela</surname><given-names>T</given-names></name><name><surname>Hoffmann-Sommergruber</surname><given-names>K</given-names></name><name><surname>Ivancevich</surname><given-names>JC</given-names></name><name><surname>Khaltaev</surname><given-names>N</given-names></name><name><surname>Knol</surname><given-names>EF</given-names></name><name><surname>Kuna</surname><given-names>P</given-names></name><name><surname>Larenas-Linnemann</surname><given-names>D</given-names></name><name><surname>Mullol</surname><given-names>J</given-names></name><name><surname>Naclerio</surname><given-names>R</given-names></name><name><surname>Ohta</surname><given-names>K</given-names></name><name><surname>Okamoto</surname><given-names>Y</given-names></name><name><surname>O&#x02019;Mahony</surname><given-names>L</given-names></name><name><surname>Onorato</surname><given-names>GL</given-names></name><name><surname>Papadopoulos</surname><given-names>NG</given-names></name><name><surname>Pfaar</surname><given-names>O</given-names></name><name><surname>Samolinski</surname><given-names>B</given-names></name><name><surname>Schwarze</surname><given-names>J</given-names></name><name><surname>Toppila-Salmi</surname><given-names>S</given-names></name><name><surname>Teresa Ventura</surname><given-names>M</given-names></name><name><surname>Valiulis</surname><given-names>A</given-names></name><name><surname>Yorgancioglu</surname><given-names>A</given-names></name><name><surname>Zuberbier</surname><given-names>T</given-names></name></person-group><article-title>Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: an ARIA-EAACI statement</article-title><source>Allergy</source><year>2020</year><pub-id pub-id-type="doi">10.1111/all.14302</pub-id><?supplied-pmid 32535955?><pub-id pub-id-type="pmid">32535955</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wollenberg</surname><given-names>A</given-names></name><name><surname>Flohr</surname><given-names>C</given-names></name><name><surname>Simon</surname><given-names>D</given-names></name><name><surname>Cork</surname><given-names>MJ</given-names></name><name><surname>Thyssen</surname><given-names>JP</given-names></name><name><surname>Bieber</surname><given-names>T</given-names></name><name><surname>de Bruin-Weller</surname><given-names>MS</given-names></name><name><surname>Weidinger</surname><given-names>S</given-names></name><name><surname>Deleuran</surname><given-names>M</given-names></name><name><surname>Taieb</surname><given-names>A</given-names></name><name><surname>Paul</surname><given-names>C</given-names></name><name><surname>Trzeciak</surname><given-names>M</given-names></name><name><surname>Werfel</surname><given-names>T</given-names></name><name><surname>Seneschal</surname><given-names>J</given-names></name><name><surname>Barbarot</surname><given-names>S</given-names></name><name><surname>Darsow</surname><given-names>U</given-names></name><name><surname>Torrelo</surname><given-names>A</given-names></name><name><surname>Stalder</surname><given-names>JF</given-names></name><name><surname>Svensson</surname><given-names>&#x000c5;</given-names></name><name><surname>Hijnen</surname><given-names>D</given-names></name><name><surname>Gelmetti</surname><given-names>C</given-names></name><name><surname>Szalai</surname><given-names>Z</given-names></name><name><surname>Gieler</surname><given-names>U</given-names></name><name><surname>De Raeve</surname><given-names>L</given-names></name><name><surname>Kunz</surname><given-names>B</given-names></name><name><surname>Spuls</surname><given-names>P</given-names></name><name><surname>von Kobyletzki</surname><given-names>LB</given-names></name><name><surname>F&#x000f6;lster-Holst</surname><given-names>R</given-names></name><name><surname>Chernyshov</surname><given-names>PV</given-names></name><name><surname>Cristen-Zaech</surname><given-names>S</given-names></name><name><surname>Heratizadeh</surname><given-names>A</given-names></name><name><surname>Ring</surname><given-names>J</given-names></name><name><surname>Vestergaard</surname><given-names>C</given-names></name></person-group><article-title>European Task Force on Atopic Dermatitis (ETFAD) statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-infection and atopic dermatitis</article-title><source>J Eur Acad Dermatol Venereol</source><year>2020</year><pub-id pub-id-type="doi">10.1111/jdv.16411</pub-id><?supplied-pmid 32515512?><pub-id pub-id-type="pmid">32515512</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Bruin-Weller</surname><given-names>M</given-names></name><name><surname>Tha&#x000e7;i</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>CH</given-names></name><name><surname>Reich</surname><given-names>K</given-names></name><name><surname>Cork</surname><given-names>MJ</given-names></name><name><surname>Radin</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Akinlade</surname><given-names>B</given-names></name><name><surname>Gadkari</surname><given-names>A</given-names></name><name><surname>Eckert</surname><given-names>L</given-names></name><name><surname>Hultsch</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Pirozzi</surname><given-names>G</given-names></name><name><surname>Graham</surname><given-names>NMH</given-names></name><name><surname>Shumel</surname><given-names>B</given-names></name></person-group><article-title>Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF&#x000c9;)</article-title><source>Br J Dermatol</source><year>2018</year><volume>178</volume><issue>5</issue><fpage>1083</fpage><lpage>1101</lpage><pub-id pub-id-type="doi">10.1111/bjd.16156</pub-id><?supplied-pmid 29193016?><pub-id pub-id-type="pmid">29193016</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrucci</surname><given-names>S</given-names></name><name><surname>Romagnuolo</surname><given-names>M</given-names></name><name><surname>Angileri</surname><given-names>L</given-names></name><name><surname>Berti</surname><given-names>E</given-names></name><name><surname>Tavecchio</surname><given-names>S</given-names></name></person-group><article-title>Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports</article-title><source>J Eur Acad Dermatol Venereol</source><year>2020</year><pub-id pub-id-type="doi">10.1111/jdv.16527</pub-id><?supplied-pmid 32330323?><pub-id pub-id-type="pmid">32330323</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Auria</surname><given-names>E</given-names></name><name><surname>Anania</surname><given-names>C</given-names></name><name><surname>Cuomo</surname><given-names>B</given-names></name><name><surname>Decimo</surname><given-names>F</given-names></name><name><surname>Indirli</surname><given-names>GC</given-names></name><name><surname>Mastrorilli</surname><given-names>V</given-names></name><name><surname>Santoro</surname><given-names>A</given-names></name><name><surname>Sartorio</surname><given-names>MA</given-names></name><name><surname>Veronelli</surname><given-names>E</given-names></name><name><surname>Caffarelli</surname><given-names>C</given-names></name><name><surname>Marseglia</surname><given-names>GL</given-names></name><name><surname>Calvani</surname><given-names>M</given-names></name><collab>Food Allergy Study Group TISOPAAIS</collab></person-group><article-title>COVID-19 and food allergy in children</article-title><source>Acta Biomed.</source><year>2020</year><volume>91</volume><issue>2</issue><fpage>204</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.23750/abm.v91i2.9614</pub-id><?supplied-pmid 32420946?><pub-id pub-id-type="pmid">32420946</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casale</surname><given-names>TB</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Nowak-Wegrzyn</surname><given-names>A</given-names></name></person-group><article-title>Acute at home management of anaphylaxis during the Covid-19 pandemic</article-title><source>J Allergy Clin Immunol Pract.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.jaip.2020.04.022</pub-id><?supplied-pmid 32485237?><pub-id pub-id-type="pmid">32485237</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Rademaker</surname><given-names>M</given-names></name><name><surname>Baker</surname><given-names>C</given-names></name><name><surname>Foley</surname><given-names>P</given-names></name></person-group><article-title>COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: an Australia/New Zealand consensus statement</article-title><source>Australas J Dermatol</source><year>2020</year><pub-id pub-id-type="doi">10.1111/ajd.13313</pub-id><?supplied-pmid 32441058?><pub-id pub-id-type="pmid">32441058</pub-id></element-citation></ref></ref-list></back></article>